AUTHORS
Ian Bouligny, M.D., Tapan Kadia I, MD2, Courtney DiNardo, MD, MSCE3, Naval Daver, MD4, Gautam Borthakur, MD5, Naveen Pemmaraju, MD6, Ghayas C. Issa, MD7, Maro Ohanian, DO8, Nicholas Short, MD9, Yesid Alvarado Valero, MD10, Guillermo Montalban-Bravo, MD11, Elias Jabbour, MD12, Musa Yilmaz, MD13, Kelly Sharon Chien, MD14, Steven Kornblau, MD15, Danielle Hammond, MD16, Fadi G. Haddad, MD17, Koichi Takahashi, MD,PhD18, Lucia Masarova, MD19, Alexandre Bazinet, MD, MSc20, Mahesh Swaminathan, MD21, Eitan Kugler, MD PhD22, Hussein Ali Abbas, MD, PhD23, Wei Ying Jen, BM BCh, FRCPath24, Jayastu Senapati, MBBS, MD, DM25, Alex Bataller, MD, PhD26, Abhishek Maiti, MBBS27, Guillermo Garcia-Manero, MD28, Farhad Ravandi, MD29
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
A protective environment (PE), comprising barrier precautions, 0.2 micron water filtration, daily bathroom cleaning, isolation, and visitor limitations, is routinely used to reduce infection risk during AML induction. However, evidence supporting PE precautions predate venetoclax-based therapy, universal antimicrobial prophylaxis, advances in supportive care, and more liberal G-CSF use. No data exists to guide the use of PEs with contemporary venetoclax-based induction strategies in AML.
Methods
This was a preplanned, pooled analysis of four trials involving patients with newly diagnosed AML treated at MD Anderson Cancer Center (2018–2025) who received lower-intensity (cladribine, low-dose cytarabine, and venetoclax [CLAD-LDAC-ven] or decitabine-venetoclax [dac-ven]) or high-intensity regimens (cladribine or fludarabine, cytarabine, idarubicin, and venetoclax [CLIA-ven or FLAG-ida-ven]). Co-primary endpoints were (1) neutropenic fever and (2) grade ≥3 infection rates (CTCAE v5.0) during cycle 1.
All patients were hospitalized and received antimicrobial prophylaxis. PE assignment was at physician discretion. Toxicity grading was blinded to PE status. Standardized mean differences (SMDs) were computed for four pre-specified covariates (age, Charlson comorbidity index [CCI], ECOG, ELN 2022 risk); any SMD >0.10 triggered 1:1 nearest-neighbor propensity score matching (caliper 0.2 SD). The study was powered to detect a 15% absolute reduction in neutropenic fever induction events (80% power, α = 0.025 per endpoint, Bonferroni-corrected), requiring 488 patients.
Results
Of 495 patients (217 CLAD-LDAC-ven, 118 dac-ven, 107 CLIA-ven, 53 FLAG-ida-ven), 329 (66%) were treated in a PE and 166 (34%) in a standard hospital room (no PE). PE patients were older (median 68.1 vs. 58.3 years, p < 0.001), had higher CCI (5 vs. 4, p < 0.001), and were more likely to receive lower-intensity therapy (77% vs. 50%, p < 0.001) with less G-CSF (29% vs. 43%, p = 0.002). ECOG (median 1 vs. 1, p = 0.73), ELN 2022 risk (favorable/intermediate/adverse: 21/17/62% vs. 18/23/59%, p = 0.23), and race/ethnicity (White 78% vs. 78%, Black 8% vs. 8%, Hispanic 8% vs. 8%; p = 0.89) were similar. SMDs exceeded the prespecified cutoff of 0.10 for age (0.80) and CCI (0.44), triggering propensity matching per the preplanned analysis, yielding 137 pairs (n = 274). Post-matching SMDs were ≤0.10 for all covariates except age (residual SMD 0.15; median 65.1 vs. 63.8 years).
In the propensity-matched analysis, PE precautions did not reduce neutropenic fever (PE 64.2% vs. non-PE 59.9%, p = 0.57) or grade ≥3 infections (48.9% vs. 48.9%, p > 0.99) compared to standard hospitalization. Conditional logistic regression confirmed no effect: the odds ratio (OR) for neutropenic fever in the PE was 1.17 (95% CI 0.75–1.84), and the OR for grade ≥3 infection was 1.00 (0.63–1.60). Results were consistent in the full unmatched cohort (neutropenic fever: 58.4% vs. 62.7%, p = 0.38; infection: 45.6% vs. 50.6%, p = 0.30) and across both lower- and high-intensity strata. No subgroup, stratified by age, ECOG, CCI, ELN 2022, treatment intensity, TP53, NPM1, FLT3, or AML-MR, demonstrated PE benefit (all p-values non-significant).
Between PE and no PE cohorts, matched secondary endpoints did not differ: 30-day mortality (3.6% vs. 2.2%, p = 0.72), 60-day mortality (9.5% vs. 6.6%, p = 0.51), ICU admission (5.1% vs. 8.8%, p = 0.34), hospitalization duration (32 vs. 31 days, p = 0.14), day 28 composite CR (CRc; CR + CRi: 66.7% vs. 66.9%, p > 0.99), day 28 MRD negativity among CRc responders (75.6% vs. 77.8%, p = 0.85), median OS (965 vs. 896 days; adjusted multivariable HR 1.00, 0.71–1.41), and EFS (517 vs. 417 days; adjusted multivariable HR 0.96, 0.69–1.33). No infection subtype or etiology differed in the matched cohort.
Conclusions
In this study evaluating PE precautions in AML induction, the PE did not reduce the risk of neutropenic fever or grade ≥3 infections in cycle 1. Early mortality, ICU admissions, CRc rates, and MRD negativity rates did not differ between PE and non-PE cohorts. With current standard AML induction protocols including universal antimicrobial prophylaxis, liberal G-CSF, and regimens optimized to shorten the duration of neutropenia, this study did not identify additional measurable benefit from treating patients in a PE. Future studies should focus on optimizing nutrition, sleep, and physical activity in induction AML protocols.
DISCLOSURES
Ian Bouligny, M.D.: No relevant conflicts of interest to declare.